Serum collagen crosslinks as markers of bone turn-over during GH replacement therapy in growth hormone deficient adults.

What Was Tested

This randomized controlled trial looks at Exogenous HGH, sermorelin & older GHRPs (why they're passed over).

Bone metabolism is an important target for GH replacement therapy.

However, in adults, treatment periods exceeding 12 months are required for a positive effect of GH on bone mineral density.

Thus, to detect an early effect of GH on bone, markers of bone turn-over are important.

Who Took Part

According to the abstract, 17 women were involved.

PubMed indexes the participants as adults and middle-aged adults, both men and women.

How the Study Was Run

In design terms this was a randomized, double-blind and placebo-controlled study.

The women were allocated by chance, so the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) group and the comparison group should start out alike.

Blinding on both sides kept the women and researchers unaware of who received Exogenous HGH, sermorelin & older GHRPs (why they're passed over).

A placebo (an inactive look-alike) gave the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) group a baseline to be compared against.

Bone formation was analysed using serum bone alkaline phosphatase (BAP) and serum osteocalcin (OC).

Bone resorption was analysed using serum pyridinoline (PYR) and serum deoxypyridinoline (DPYR).

Bone mineral density (BMD) was determined by dual energy X-ray absorptiometry (DEXA).

What Was Measured

The subject headings attached to it are Alkaline Phosphatase, Amino Acids, Biomarkers, Bone Density, Bone Diseases, Endocrine, Bone Remodeling and Chromatography, High Pressure Liquid.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in 17 women.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The abstract goes on to report its results in about 6 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 1998 (Clinical endocrinology), a journal based in England.

More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.